Winter virus season so far is not too bad, but doctors worry about suffering to come

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

Human 'mini-noses' help explain why RSV infections are more severe in children than in adults

An infection with respiratory syncytial virus (RSV) typically affects infants much harder than adults. While adults usually ...

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

Do you have the mystery ‘2025 throat virus’ going around? Here’s what it could be.

TikTok, X, and Instagram are flooded with videos about a mysterious “2025 throat virus” that’s making everyone sick. The ...

Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the E ...
Dermatology Advisor

Review Affirms Safety and Effectiveness of COVID-19, RSV, and Influenza Vaccines

RSV, and influenza show continued safety and substantial effectiveness against hospitalization across various populations.
News-Medical.Net on MSN

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

By Hugo Francisco de Souza By combining nationwide health data with elegant immunology experiments, researchers reveal how ...

Understanding the '2025 Throat Virus': What You Need to Know

Flu Statistics: The CDC reports that the 2025 Southern Hemisphere seasonal influenza vaccine reduced influenza-associated hospitalizations by nearly 50%. Thousands of deaths in the U.S. each year are ...
Becker's Hospital Review

FDA to reexamine infant RSV therapies

FDA reexamine infant RSV therapies with Sanofi, AstraZeneca, and Merck amid safety concerns and data review under new FDA leadership.

FDA launches safety review of RSV infant drugs as RFK Jr. scrutinizes immunizations

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

Exclusive-US FDA launches fresh safety scrutiny of approved RSV therapies for infants

By Dan Levine and Patrick Wingrove Dec 9 (Reuters) - U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for ...